Patient Satisfaction Results Highlight Potential of Francis Medical’s Vanquish System

According to a recent LinkedIn post from Francis Medical, new patient satisfaction data from the VAPOR 2 study appear to underscore the potential of the company’s Vanquish thermal ablation technology for prostate tissue. The post cites comments from Dr. Arvin K. George of Johns Hopkins, noting that most patients reportedly experienced no pain, quickly returned to daily activities, and showed high satisfaction at 12 months.

The post highlights that 93% of VAPOR 2 patients were described as extremely satisfied or satisfied at 12 months, with minimal to no pain reported, and reiterates that the Vanquish System is FDA-cleared for thermal ablation of targeted prostate tissue via a transurethral approach. For investors, these reported satisfaction metrics may signal strong clinical acceptance potential and could support commercial adoption in urology settings, although actual revenue impact will depend on reimbursement, competitive dynamics in prostate therapies, and execution of market access and sales strategies.